The therapeutic effect of Rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end-stage hypertension in rats

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 9, 2012, Pages 2227-2237

  Zhang, W B ^a   Du, Q J ^a   Li, H ^a   Sun, A J ^a   Qiu, Z H ^a   Wu, C N ^a   Zhao, G ^a   Gong, H ^a   Hu, K ^a   Zou, Y Z ^a   Ge, J B ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A (HMG CoA) reductase inhibitors; Apoptosis; Cardiac remodelling; Fibrosis; Hypertrophy; Old aged spontaneously hypertensive rats; Rosuvastatin

Indexed keywords

ANGIOTENSIN RECEPTOR; BAD PROTEIN, RAT; BIRC5 PROTEIN, RAT; CASP3 PROTEIN, RAT; CASPASE 3; FLUOROBENZENE; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, RAT; MICROTUBULE ASSOCIATED PROTEIN; NERVE PROTEIN; PROTEIN BAD; PROTEIN KINASE C; PROTEIN KINASE C BETA; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE;

ANIMAL; APOPTOSIS; ARTICLE; DRUG EFFECT; FIBROSIS; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HYPERTENSION; HYPERTROPHY; MALE; METABOLISM; PATHOLOGY; RAT; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT;

ANIMALS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CASPASE 3; FIBROSIS; FLUOROBENZENES; FORKHEAD TRANSCRIPTION FACTORS; HYPERTENSION; HYPERTROPHY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MYOCYTES, CARDIAC; NERVE TISSUE PROTEINS; PROTEIN KINASE C; PYRIMIDINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ANGIOTENSIN; SIGNAL TRANSDUCTION; SULFONAMIDES; VENTRICULAR REMODELING;

EID: 84865409081     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01536.x     Document Type: Article

References (41)

1. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365: 217-23.
2. Heagerty AM, Heerkens EH, Izzard AS. Small artery structure and function in hypertension. J Cell Mol Med. 2010; 14: 1037-43.
3. Liu HR, Tao L, Gao E, et al. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res. 2004; 62: 135-44.
4. Marzoll A, Melchior-Becker A, Cipollone F, et al. Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment? J Cell Mol Med. 2009; 15: 232-43.
5. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004; 43: 642-8.
6. Sicard P, Zeller M, Dentan G, et al. Beneficial effects of statin therapy on survival in hypertensive patients with acute myocardial infarction: data from the RICO survey. Am J Hypertens. 2007; 20: 1133-9.
7. Domanski M, Coady S, Fleg J, et al. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta Blocker Evaluation of Survival Trial [BEST]). Am J Cardiol. 2007; 99: 1448-50.
8. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-78.
9. Ridker PM, Danielson E, Fonseca FAH, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009; 373: 1175-82.
10. Zhao LL, Chen HJ, Chen JZ, et al. Losartan reduced connexin43 expression in left ventricular myocardium of spontaneously hypertensive rats. J Zhejiang Univ Sci B. 2008; 9: 448-54.
11. Sano M, Minamino T, Toko H, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007; 446: 444-8.
12. Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ Res. 2000; 87: 1123-32.
13. Connelly KA, Kelly DJ, Zhang Y, et al. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res. 2007; 76: 280-91.
14. Chang SA, Kim YJ, Lee HW, et al. Effect of rosuvastatin on cardiac remodelling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy. Hypertension. 2009; 54: 591-7.
15. Mourad J, Bertrand M. Impact of antihypertensive treatment on mortality: a late-break analysis of recent clinical trials in hypertension. J Hypertens. 2010; 28: 395-6.
16. Loch D, Levick S, Hoey A, et al. Rosuvastatin attenuates hypertension-induced cardiovascular remodelling without affecting blood pressure in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol. 2006; 47: 396-404.
17. Saka M, Obata K, Ichihara S, et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol. 2006; 47: 770-9.
18. Susic D, Varagic J, Ahn J, et al. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol. 2003; 42: 1091-7.
19. Prandin MG, Cicero AF, Dormi A, et al. Prospective evaluation of the effect of statins on blood pressure control in hypertensive patients in clinical practice. Nutr Metab Cardiovasc Dis. 2010; 20: 512-8.
20. Luo JD, Zhang WW, Zhang GP, et al. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol. 1999; 26: 903-8.
21. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001; 108: 1429-37.
22. Tomohiro A, Kimura S, He H, et al. Regional blood flow in Dahl-Iwai salt-sensitive rats and the effects of dietary L-arginine supplementation. Am J Physiol. 1997; 272: 1013-9.
23. Suzuki J, Matsubara H, Urakami M, et al. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res. 1993; 73: 439-47.
24. Jiang X, Tsitsiou E, Herrick SE, et al. MicroRNAs and the regulation of fibrosis. FEBS J. 2010; 277: 2015-21.
25. Sola S, Mir MQ, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006; 47: 332-7.
26. Thambidorai SK, Deshmukh AR, Walters RW, et al. Impact of statin use on heart failure mortality. Int J Cardiol. 2011; 147: 438-43.
27. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007; 357: 2248-61.
28. Krum H. UNIVERSE: rosuvastatin has no effect on ventricular remodelling. Presented at the annual meeting of the American College of Cardiology; Atlanta, Georgia; March 13, 2006.
29. Fabris B, Candido R, Bortoletto M, et al. Stimulation of cardiac apoptosis in ovariectomized hypertensive rats: potential role of the renin-angiotensin system. J Hypertens. 2011; 29: 273-81.
30. Kossmehl P, Kurth E, Faramarzi S, et al. Mechanisms of apoptosis after ischemia and reperfusion: role of the renin-angiotensin system. Apoptosis. 2006; 11: 347-58.
31. Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis. Circulation. 2002; 105: 530-6.
32. Reeve JLV, Duffy AM, O'Brien T, et al. Don't lose heart - therapeutic value of apoptosis prevention in the treatment of cardiovascular disease. J Cell Mol Med. 2005; 9: 609-22.
33. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004; 109: III39-43.
34. Revenco D, Morgan JP. Metabolic modulation and cellular therapy of cardiac dysfunction and failure. J Cell Mol Med. 2009; 13: 811-25.
35. Tateishi K, Takehara N, Matsubara H, et al. Stemming heart failure with cardiac- or reprogrammed-stem cells. J Cell Mol Med. 2008; 12: 2217-32.
36. Cismasiu VB, Radu E, Popescu LM. miR-193 expression differentiates telocytes from other stromal cells. J Cell Mol Med. 2011; 15: 1071-4.
37. Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res. 2011; 89: 265-72.
38. Latronico MV, Condorelli G. MicroRNAs and cardiac pathology. Nat Rev Cardiol. 2009; 6: 419-29.
39. Bauersachs J. Regulation of myocardial fibrosis by microRNAs. J Cardiovasc Pharmacol. 2010; 56: 454-9.
40. Ohtani K, Dimmeler S. Control of cardiovascular differentiation by microRNAs. Basic Res Cardiol. 2011; 106: 5-11.
41. Mishra PK, Tyagi N, Kumar M, et al. MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med. 2009; 13: 778-89.